Charles River Labs Appoints Glenn Coleman as New CFO

Details

announced on February 18, 2026, the appointment of Glenn Coleman as its new Corporate Executive Vice President and Chief Financial Officer, effective April 6, 2026. Mr. Coleman brings over 30 years of financial and operational management experience, including senior leadership roles in the healthcare sector. His compensation package includes a base salary of $800,000 annually, a target bonus of 85% of his base salary, an annual stock award with a grant value of $3,000,000, a one-time new hire cash award of $1,875,000, and a one-time new hire equity award with a grant value of $3,500,000.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.